FAST TRACK ALGORITHM: HOW TO DIFFERENTIATE A "SCLERODERMA PATTERN" FROM A "NON-SCLERODERMA PATTERN"

AUTHORS

V. Smith[1]*, A. Vanhaecke[2]*, AL. Herrick[3], O. Distler[4], MG Guerra[5], CP. Denton[6], E. Deschepper[7], I. Foeldvari[8], M. Gutierrez[9], E. Hachulla[10], F. Ingegnoli[11], S. Kubo[12], U. Müller-Ladner[13], V. Riccieri[14], JM. van Laar[15], MC. Vonk[16], U. Walker[17], M. Cutolo[18] *for* the EULAR Study Group on Microcirculation in Rheumatic Diseases.

AFFILIATIONS

1. Department of Internal Medicine, Ghent University; Department of Rheumatology, Ghent University Hospital; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium. vanessa.smith@ugent.be.

2. Department of Internal Medicine, Ghent University; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium. amber.vanhaecke@ugent.be.

3. Division of Musculoskeletal & Dermatological Sciences, The University of Manchester, Salford Royal NHS Foundation Trust; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. ariane.herrick@manchester.ac.uk

4. Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland. oliver.distler@usz.ch

5. Rheumatology Department, Centro Hospitalar Vila Nova de Gaia/Espinho, Vil Nova de Gaia, Portugal. mlgomesg@gmail.com

24   6. Department of Rheumatology, University College London, Royal Free Hospital, London,

25   UK. c.denton@medsch.ucl.ac.uk

26   7. Biostatistics Unit, Department of Public Health, Ghent University, Ghent, Belgium.

27   ellen.deschepper@ugent.be

28   8. Centre for Paediatric and Adolescent Rheumatology, Hamburg, Germany. foeldvari@t-

29   online.de

30   9. Division of Musculoskeletal and Rheumatic Disorders, Instituto Nacional de Rehabilitación,

31   Mexico City, Mexico. dr.gmarwin@gmail.com

32   10. Univ. Lille, CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre

33   de Référence des Maladies Systémiques et Auto-Immunes Rares du Nord-Ouest (CERAINO),

34   LIRIC, INSERM, Lille, France. ehachulla2@yahoo.fr

35   11. Department of Clinical Sciences and Community Health, University of Milan; Division of

36   Rheumatology, ASST G. Pini, Milan, Italy. francesca.ingegnoli@unimi.it

37   12. The First Department of Internal Medicine, University of Occupational and Environmental

38   Health, Fukuoka, Japan. kubosato@med.uoeh-u.ac.jp

39   13. Department of Rheumatology and Clinical Immunology, Justus-Liebig University of

40   Giessen, Campus Kerckhoff, Bad Nauheim, Germany. u.mueller-ladner@kerckhoff-klinik.de

41   14. Department of Internal Medicine and Medical Specialties, Sapienza University of Rome,

42   Italy. valeria.riccieri@uniroma1.it

43   15. Department of Rheumatology and Clinical Immunology, University Medical Center

44   Utrecht, Utrecht, The Netherlands. j.m.vanlaar@umcutrecht.nl

45   16. Department of Rheumatology, Radboud University Medical Center, Nijmegen, The

46   Netherlands. madelon.vonk@radboudumc.nl

47   17. Department of Rheumatology, University Hospital Basel, Basel, Switzerland.

48   ulrich.walker@usb.ch

49   18. Research Laboratory and Academic Division of Clinical Rheumatology, Department of

50   Internal Medicine, University of Genoa, IRCCS San Martino Polyclinic Hospital, Genoa, Italy.

51   mcutolo@unige.it.

52   *Vanessa Smith and Amber Vanhaecke contributed equally to this study.

53

54   **CORRESPONDING AUTHOR**

55   Vanessa Smith,

56   Department of Rheumatology, Ghent University Hospital.

57   Corneel Heymanslaan 10, 9000 Ghent, Belgium.

58   E-mail: vanessa.smith@ugent.be.

59   Phone: +32 (0)9 332 89 93 and fax: +32 (0)9 332 38 03.

STATEMENT OF AUTHOR CONTRIBUTION, AGREEMENT AND DECLARATION

60

Vanessa Smith: Ideation of the study, substantial contributions to the design of the study,
acquisition of data, analysis and interpretation of data, drafting of the article, critical revision
of the intellectual content, final approval of the version to be published.

61
62
63

Amber Vanhaecke: Acquisition of data, analysis and interpretation of data, drafting of the
article, critical revision of the intellectual content, final approval of the version to be published.

64
65

Ariane L. Herrick: Analysis and interpretation of data, drafting of the article, critical revision
of the intellectual content, final approval of the version to be published.

66
67

Oliver Distler: Analysis and interpretation of data, drafting of the article, critical revision of
the intellectual content, final approval of the version to be published.

68
69

Miguel Guerra: Acquisition of data, analysis and interpretation of data, drafting of the article,
critical revision of the intellectual content, final approval of the version to be published.

70
71

Christopher Denton: Analysis and interpretation of data, drafting of the article, critical
revision of the intellectual content, final approval of the version to be published.

72
73

Ellen Deschepper: Analysis and interpretation of data, drafting of the article, critical revision
of the intellectual content, final approval of the version to be published.

74
75

Ivan Foeldvari: Analysis and interpretation of data, drafting of the article, critical revision of
the intellectual content, final approval of the version to be published.

76
77

Marwin Gutierrez: Analysis and interpretation of data, drafting of the article, critical revision
of the intellectual content, final approval of the version to be published.

78
79

4

80   **Eric Hachulla:** Analysis and interpretation of data, drafting of the article, critical revision of

81   the intellectual content, final approval of the version to be published.

82   **Francesca Ingegnoli:** Analysis and interpretation of data, drafting of the article, critical

83   revision of the intellectual content, final approval of the version to be published.

84   **Satoshi Kubo:** Analysis and interpretation of data, drafting of the article, critical revision of

85   the intellectual content, final approval of the version to be published.

86   **Ulf Müller-Ladner:** Analysis and interpretation of data, drafting of the article, critical revision

87   of the intellectual content, final approval of the version to be published.

88   **Valeria Riccieri:** Analysis and interpretation of data, drafting of the article, critical revision of

89   the intellectual content, final approval of the version to be published.

90   **Jacob M. van Laar:** Analysis and interpretation of data, drafting of the article, critical revision

91   of the intellectual content, final approval of the version to be published.

92   **Madelon C. Vonk:** Analysis and interpretation of data, drafting of the article, critical revision

93   of the intellectual content, final approval of the version to be published.

94   **Ulrich Walker:** Analysis and interpretation of data, drafting of the article, critical revision of

95   the intellectual content, final approval of the version to be published.

96   **Maurizio Cutolo:** Substantial contributions to the design of the study, analysis and

97   interpretation of data, drafting of the article, critical revision of the intellectual content, final

98   approval of the version to be published.

131   **ACKNOWLEDGEMENTS**

137 A special thanks goes to Ann Van den Broecke and Charlotte Carton for their assistance in

138 completing the database.

139

140 **FUNDING SOURCE DECLARATION**

ABSTRACT

Objectives: This study was designed to propose a simple "Fast Track algorithm" for capillaroscopists of any level of experience to differentiate "scleroderma patterns" from "non-scleroderma patterns" on capillaroscopy and to assess its inter-rater reliability.

Methods: Based on existing definitions to categorise capillaroscopic images as "scleroderma patterns" and taking into account the real life variability of capillaroscopic images described standardly according to the European League Against Rheumatism (EULAR) Study Group on Microcirculation in Rheumatic Diseases, a fast track decision tree, the "Fast Track algorithm" was created by the principal expert (VS) to facilitate swift categorisation of an image as "non-scleroderma pattern (category 1)" or "scleroderma pattern (category 2)". Mean inter-rater reliability between all raters (experts/attendees) of the 8th EULAR course on capillaroscopy in Rheumatic Diseases (Genoa, 2018) and, as external validation, of the 8th European Scleroderma Trials and Research group (EUSTAR) course on systemic sclerosis (SSc) (Nijmegen, 2019) versus the principal expert, as well as reliability between the rater pairs themselves was assessed by mean Cohen's and Light's kappa coefficients.

Results: Mean Cohen's kappa was 1/0.96 (95% CI 0.95-0.98) for the 6 experts/135 attendees of the 8th EULAR capillaroscopy course and 1/0.94 (95% CI 0.92-0.96) for the 3 experts/85 attendees of the 8th EUSTAR SSc course. Light's kappa was 1/0.92 at the 8th EULAR capillaroscopy course, and 1/0.87 at the 8th EUSTAR SSc course.

Conclusion: For the first time, a clinical expert based fast track decision algorithm has been developed to differentiate a "non-scleroderma" from a "scleroderma pattern" on capillaroscopic images, demonstrating excellent reliability when applied by capillaroscopists with varying levels of expertise versus the principal expert and corroborated with external validation.

9

168   **KEYWORDS**

169   EULAR Study Group on Microcirculation in Rheumatic Diseases, capillaroscopy, reliability,

170   "scleroderma patterns", novices, experts, algorithm.

ABBREVIATIONS

171 **ABBREVIATIONS**

172 ACR   *American College of Rheumatology*

173 CI   *Confidence Interval*

174 EULAR   *European League Against Rheumatism*

175 EULAR SG MC/RD   *EULAR Study Group on Microcirculation in Rheumatic Diseases*

176 EUSTAR   *European Scleroderma Trials and Research group*

177 NVC   *nailfold videocapillaroscopy*

178 SSc   *systemic sclerosis*

1. INTRODUCTION

The "scleroderma pattern" on capillaroscopy has been incorporated into the 2013 American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) classification criteria, as well as in criteria to facilitate a (very) early diagnosis of systemic sclerosis (SSc) (1-3). Its importance is based on the fact that the combination of a "scleroderma pattern" and SSc specific antibodies has the highest performance characteristics to discern in a Raynaud's phenomenon population who will and who will not develop SSc (4).

In 1973 and more detailed in 1981, Maricq et al. was the first to describe key capillary abnormalities of a "scleroderma pattern" using "wide-field" capillary microscopy as "enlargement of capillary loops, loss of capillaries ('loop drop-out'), disruption of the normal capillary architecture and haemorrhages" (5, 6). Moreover, in her seminal quantitative study she measured with the stereomicroscopic technique the apical diameter of "definitely enlarged" capillaries, and found a mean apical diameter of 47.7μm ± 5.8 to be specific for scleroderma spectrum diseases (7). This finding was adopted and further developed by Cutolo et al. who likewise defined "giant capillaries" with the nailfold videocapillaroscopic (NVC) technique as homogeneously enlarged capillaries with a normal shape and apical diameter over 50μm (8). The presence of these giant capillaries on NVC is interesting, as it allows distinction between SSc and non-SSc with over 95.6% specificity (9, 10). Of note, giant capillaries are the hallmark of the "early" and "active" scleroderma patterns, whilst the "late" scleroderma pattern is characterised by the combination of severe loss of capillaries combined with abnormal shapes ("[neo-] angiogenesis") (7, 8).

Even though the classification of a capillaroscopic image as "scleroderma pattern" or not has a high inter-rater reliability between trained capillaroscopists, to the untrained rheumatologist this

202   classification may be very challenging (11-13). One of the reasons may be the vast variety of

203   non-specific abnormalities of capillaroscopic characteristics (i.e. of capillary density, capillary

204   dimension, capillary morphology and haemorrhages) that may be found in the general

205   population (see below and in Supplementary File 1).

206   To facilitate the non-trained capillaroscopist in easily classifying an image as "scleroderma

207   pattern" or "non-scleroderma pattern", the EULAR Study Group on Microcirculation in

208   Rheumatic Diseases (EULAR SG MC/RD), a non-profit international network of expert centres

209   established in 2014 which has as its main (research) focus to facilitate standardization of

210   different non-invasive techniques, decided to create a swiftly trainable decision tree, the "Fast

211   Track algorithm", based on existing definitions to categorise capillaroscopic images into the

212   category of "scleroderma patterns" or into the category of "non-scleroderma patterns".

213   Additionally, the EULAR SG MC/RD decided to assess the reliability of raters using this

214   decision tree to classify capillaroscopic images. The key advantage of a fastly trainable, reliable

215   decision tree would be that any capillaroscopist of any level of experience would be able to use

216   this, knowing that he/she would rate likewise to a principal capillaroscopy expert, without the

217   need to evaluate each single capillaroscopic characteristic that can be evaluated in

218   capillaroscopy for research aims (see below and Supplementary File 1).

2. METHODS

2.1. "Fast Track algorithm"

Based on the standard interpretation of capillaroscopic images by the EULAR SG MC/RD, more specifically of the following capillaroscopic characteristics: capillary density, capillary dimension, presence of abnormal capillary shapes and presence of haemorrhages (see Supplementary File 1) and based on the key elements of the "scleroderma pattern", a decision tree (i.e. the "Fast Track algorithm") was consented by two founding members of the EULAR SG MC/RD (VS, MC) (see Figure 1). The "Fast Track algorithm" consists of three easy rules: 1) Rule number 1: the presence of ≥ 7 capillaries (capillary density) AND the absence of giant capillaries (capillary dimension) allows the rater to call the capillaroscopic image a "non-scleroderma pattern (category 1)"; 2) Rule number 2: the presence of giant capillaries or the presence of an extremely lowered capillary density (≤ 3 capillaries) in combination with abnormal shapes (= "late" scleroderma pattern) allows the capillaroscopist to call the capillaroscopic image a "scleroderma pattern (category 2)"; 3) Rule number 3: if the image does not meet rule number 1 or rule number 2 then the image is automatically classified as a "non-scleroderma pattern (category 1)" (see Figure 1).

2.2. Capillaroscopic images

Thirty representative NVC images (i.e. 14 images with "scleroderma pattern" and 16 with "non-scleroderma pattern") with good visibility, acquired by an optical probe videocapillaroscope equipped with a 200x magnification contact lens, were randomly selected from all NVC examinations of patients referred to the Ghent University Scleroderma Unit between December 2017 and June 2018 (see Supplementary File 2 for the examination set with all capillaroscopic

14

images). In the distal row, the apical diameter of dilated capillaries was reported by a trainee (MG), who had been trained by the principal expert (VS). All images were proofread by the principal expert (VS). Categorisation of images as "scleroderma pattern" or "non-scleroderma pattern" had been executed by the principal expert (VS).

2.3. Procedure of teaching the "Fast Track algorithm" and examining the raters

In the first part of this international multicentre study, a 45 min lasting lecture ("Capillaroscopy in daily practice") was given at the 8th EULAR course on capillaroscopy in Rheumatic Diseases in Genoa (September 2018) to 141 attendees, more specifically 6 experts in capillaroscopy and 135 attendees with varying levels of experience in capillaroscopy: 68 "novices", 53 "moderately experienced" and 14 "experienced" (see Table 1). In this lecture the EULAR SG MC/RD standardly assessed capillaroscopic characteristics (capillary density, capillary dimension, abnormal morphology and haemorrhages) were explained step by step by the principal expert (VS) and for the attendees' information an overview of all possible combinations of each of the capillaroscopic characteristics resulting into either "scleroderma patterns" or oppositely "non-scleroderma patterns" was taught both theoretically and applied to exemplary images (see Supplementary File 1 and 3). The "Fast Track algorithm" was applied to each capillaroscopic image and explained by the teacher, the principal expert (VS). Hence, in this interactive way, the audience was stimulated to actively learn the "Fast Track algorithm" (see Figure 1). After the teaching lecture, the attendees had the picture of the "Fast Track algorithm" at hand during the examination (see Figure 1). In addition, the PowerPoint slide of the "Fast Track algorithm" had also been projected in the room during the whole examination (see Figure 2A and 2B). The exams existed of 16 pages, containing two capillaroscopic images

265   per page (see Supplementary File 2). Next to an image the attendee was asked to choose

266   between two options by applying a cross, i.e. more specifically category 1 ("non-scleroderma

267   pattern") or category 2 ("scleroderma pattern") (see Supplementary File 2). Collaboration

268   between attendees to execute the exam was not allowed. Two trainees (AV, MG) of the

269   principal expert (VS) as well as the principal expert (VS) and the senior author (MC) supervised

270   the room to avoid any collaboration between attendees in taking the exam. Of note, the raters

271   (experts and attendees) were asked to attest their levels of expertise in capillaroscopy into one

272   of the following categories: "novices" (no experience), "moderately experienced" (< 5 years of

273   experience with capillaroscopy) and "experienced" raters (> 5 years of experience with

274   capillaroscopy).

275   In a second time, as an external validation, this procedure was repeated during the 8th European

276   Scleroderma Trials and Research group (EUSTAR) course on SSc in Nijmegen (February 2019)

277   on 88 attendees, more specifically 3 experts and 85 attendees with varying levels of knowledge

278   of capillaroscopy: 47 "novices", 29 "moderately experienced" and 9 "experienced" (see Table

279   2).

280

281   **2.4. Statistical analysis**

282   Inter-rater agreement for each rater versus the principal expert (VS), i.e. "mean index of

283   reliability", was calculated for the group of experts, "novices", "moderately experienced" raters

284   and "experienced" raters, both at the 8th EULAR course on capillaroscopy in Rheumatic

285   Diseases and for reasons of external validation, as well at the 8th EUSTAR course on SSc. To

286   this end, the mean Cohen's kappa value was reported, which is estimated by taking the mean

287   of all Cohen's kappa statistic scores between raters and the principal expert (VS) (see Figure

288   3A) (14).

289   Additionally, the agreement between all possible rater pairs, irrespective of the principal expert

290   (VS), was reflected through reporting the Light's kappa. Hence, conceivably, if the algorithms

291   should be representative for the experts (other than the principal expert) then the Light's kappa

292   should be high in between the experts (see Figure 3B) (14).

293   Thirdly, to get an idea of the percentage of raters at both courses which had a nearly perfect

294   agreement, which is a kappa of > 0.8 versus the principal expert (VS), the distribution of the

295   individual kappa's was calculated (15).

3. RESULTS

3.1. Raters

Six expert raters (MC, AH, FI, VR, AS, VS [principal expert]) and 135 attendees (68 "novices", 53 "moderately experienced" and 14 "experienced" raters, from 43 different countries) participated at the 8th EULAR course on capillaroscopy in Rheumatic Diseases and 3 expert raters (MC, MV, VS [principal expert]) and 85 attendees (47 novices, 29 moderately experienced and 9 experienced raters, from 22 different countries) participated at the 8th EUSTAR course on SSc.

3.2. Inter-rater reliability

The mean index of reliability (i.e. mean Cohen's kappa) based on 30 images was 1 for the expert raters present at the 8th EULAR course on capillaroscopy in Rheumatic Diseases (n=6) and 1 for the expert raters present at the 8th EUSTAR course on SSc (n=3). The mean index of reliability was 0.96 (95% Confidence Interval [CI] 0.95-0.98) for the attendees of the 8th EULAR course on capillaroscopy in Rheumatic Diseases (n=135) and 0.94 (95% CI 0.92-0.96) for the attendees of the 8th EUSTAR course on SSc (n=85). Subgroup analysis according to the level of experience of the attendees, demonstrated a mean Cohen's kappa of 0.98 (95% CI 0.96-0.99) and 0.93 (95% CI 0.90-0.96) for "novices" (at the 8th EULAR course on capillaroscopy in Rheumatic Diseases and 8th EUSTAR course on SSc respectively), 0.96 (95% CI 0.93-0.99) and 0.94 (95% CI 0.89-0.98) for "moderately experienced" raters (at the 8th EULAR course on capillaroscopy in Rheumatic Diseases and 8th EUSTAR course on SSc respectively) and 0.93 (95% CI 0.85-1) and 0.97 (95% CI 0.92-1) for "experienced" raters (at the 8th EULAR course on capillaroscopy in Rheumatic Diseases and 8th EUSTAR course on SSc respectively).

319   Inter-rater agreement for each possible combination of rater pairs (i.e. Light's kappa),

320   irrespective of the principal expert (VS), based on the 30 images was 1 for the expert raters

321   present at the 8th EULAR course on capillaroscopy in Rheumatic Diseases (n=6) and 1 for the

322   expert raters present at the 8th EUSTAR course on SSc (n=3). The inter-rater agreement for

323   each possible combination of rater pairs, irrespective of the principal expert was 0.92 for the

324   attendees of the 8th EULAR course on capillaroscopy in Rheumatic Diseases (n=135) and 0.87

325   for the attendees of the 8th EUSTAR course on SSc (n=85). Subgroup analysis demonstrated a

326   Light's kappa of 0.95 and 0.87 for "novices" (at the 8th EULAR course on capillaroscopy in

327   Rheumatic Diseases and 8th EUSTAR course on SSc respectively), 0.91 and 0.88 for

328   "moderately experienced" raters (at the 8th EULAR course on capillaroscopy in Rheumatic

329   Diseases and 8th EUSTAR course on SSc respectively) and 0.84 and 0.94 for "experienced"

330   raters (at the 8th EULAR course on capillaroscopy in Rheumatic Diseases and 8th EUSTAR

331   course on SSc respectively).

332

333   **3.3. Percentage of raters with high agreement versus the principal expert**

334   The distribution of the individual kappa's showed that 95% of raters at the 8th EULAR course

335   on capillaroscopy in Rheumatic Diseases in Genoa and 89% of raters at the 8th EUSTAR course

336   on SSc in Nijmegen had a kappa of > 0.8 versus the principal expert (VS).

4. DISCUSSION

This is the first international multicentre study to step forward to the need to find an easy rule of thumb decision tree (i.e. the "Fast Track algorithm") to categorise capillaroscopic images as "scleroderma pattern" or "non-scleroderma pattern". A principal expert (VS) had first classified 30 images, taken with a nailfold videocapillaroscope with a 200x magnification, as "scleroderma pattern" or "non-scleroderma pattern", the latter comprising perfectly normal images but also images with non-specific abnormalities. Then, in two renowned international training courses (the 8th EULAR course on capillaroscopy in Rheumatic Diseases and the 8th EUSTAR course on SSc) course raters (experts and attendees of different level of experience ["novices", "moderate experienced", "experienced"]) had been trained in 45 minutes by the principal expert to categorise images in the exact same way as the principal expert through exemplary teaching the "Fast Track algorithm". Subsequently, both in the pilot study at the 8th EULAR course on capillaroscopy in Rheumatic Diseases in Genoa, as well as in the external validation study at the 8th EUSTAR course on SSc in Nijmegen, an excellent inter-rater reliability, not only versus the principal expert rater (mean Cohen's kappa) but also in between the raters themselves (Light's kappa) was found in categorising capillaroscopic images as "scleroderma pattern" or as "non-scleroderma pattern". Hence, we strongly feel that this "Fast Track algorithm" may be used safely as a teaching tool in daily practice to capillaroscopists with any level of experience, with the aim to have certainty to categorise a capillaroscopic image as a "scleroderma pattern" in the same way that an expert rater does.

This swiftly trainable and reliable decision tree is important, certainly as the "scleroderma pattern" is a criterion in the new 2013 ACR/EULAR classification criteria for systemic sclerosis (3). Correct attribution (vis à vis a principal expert as repère point) of a capillaroscopic image

360   to the "scleroderma pattern" category is key to correctly denote a patient to meet the criterion

361   of "abnormal capillaroscopy" of the 2013 ACR/EULAR criteria (3).

362   One of the advantages of the "Fast Track algorithm" is that only simple capillaroscopic

363   characteristics were needed to teach the raters, more specifically, capillaroscopic characteristics

364   that have attested through literature to have a high inter-rater reliability: "capillary density"

365   (number of capillaries), "giant capillaries" (capillaries with an apical diameter ≥ 50 µm) and

366   "abnormal shapes" (13, 16-24). Rather than trying to train the eye of the rater to interpret

367   capillaroscopic images according to any combination of all existing capillaroscopic

368   characteristics that are being used nowadays in research which may be quite challenging to the

369   untrained capillaroscopists (see Supplementary File 1), with the "Fast Track algorithm" the

370   capillaroscopist only has to check three rules which automatically lead him/her to a correct

371   categorisation, more specifically into a "scleroderma pattern or "non-scleroderma pattern".

372   Additionally, we want to draw attention to the fact that the aim of this study was not to assess

373   discriminatory characteristics of capillaroscopy to differentiate between healthy controls,

374   primary Raynaud's patients and patients with secondary Raynaud's phenomenon due to SSc.

375   Landmark work on this issue has already been done (4, 25, 26). Moreover, such a research

376   question would have needed a totally different statistical approach with calculation of receiver

377   operating curves and calculation of sensitivity and specificity of capillaroscopy to discriminate

378   healthy controls and primary from secondary Raynaud's phenomenon due to SSc. In contrast,

379   our intention was to assess an expert designed decision tree, the "Fast Track algorithm", with

380   the aim to enable every capillaroscopist of any level of experience to differentiate within groups

381   of clinically relevant capillaroscopic patterns, more specifically between "the scleroderma

382   patterns" versus the "non-scleroderma patterns".

5. CONCLUSION

For the first time, a clinical expert based fast track decision algorithm has been developed to differentiate a "non-scleroderma" from a "scleroderma pattern" on capillaroscopic images. This algorithm demonstrated an excellent reliability when applied by capillaroscopists with varying levels of expertise versus the principal expert, at the 8th EULAR course on capillaroscopy in Rheumatic Diseases in Genoa and corroborated with external validation at the 8th EUSTAR course on SSc in Nijmegen.

390   **REFERENCES**

391   1.   LeRoy EC, Medsger TA, Jr. Criteria for the classification of early systemic sclerosis. J

392   Rheumatol. 2001;28(7):1573-6.

393   2.   Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al. Preliminary

394   criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study

395   from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70(3):476-81.

396   3.   van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013

397   classification criteria for systemic sclerosis: an American college of rheumatology/European

398   league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-55.

399   4.   Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al.

400   Autoantibodies and microvascular damage are independent predictive factors for the

401   progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study

402   of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis

403   Rheum. 2008;58(12):3902-12.

404   5.   Maricq HR, LeRoy EC. Patterns of finger capillary abnormalities in connective tissue

405   disease by "wide-field" microscopy. Arthritis Rheum. 1973;16(5):619-28.

406   6.   Maricq HR. Wide-field capillary microscopy. Technique and rating scale for

407   abnormalities seen in scleroderma and related disorders. Arthritis Rheum. 1981;24(9):1159-65.

408   7.   Maricq HR. Comparison of quantitative and semiquantitative estimates of nailfold

409   capillary abnormalities in scleroderma spectrum disorders. Microvasc Res. 1986;32(2):271-6.

410   8.   Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy assessment of

411   microvascular damage in systemic sclerosis. J Rheumatol. 2000;27(1):155-60.

412   9.   Lonzetti LS, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E, et al. Updating the

413   American College of Rheumatology preliminary classification criteria for systemic sclerosis:

414   addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for

415   limited scleroderma. Arthritis Rheum. 2001;44(3):735-6.

416   10.   Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma

417   diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early

418   stages of the disease. J Rheumatol. 1988;15(2):276-83.

419   11.   Smith V, Pizzorni C, De Keyser F, Decuman S, Van Praet JT, Deschepper E, et al.

420   Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a

421   systemic sclerosis cohort: a two-centre study. Ann Rheum Dis. 2010;69(6):1092-6.

422   12.   Gutierrez M, Bertolazzi C, Tardella M, Becciolini A, M DIC, Dottori M, et al.

423   Interreader reliability in assessment of nailfold capillary abnormalities by beginners: pilot study

424   of an intensive videocapillaroscopy training program. J Rheumatol. 2012;39(6):1248-55.

425   13.   Boulon C, Devos S, Mangin M, Decamps-Le Chevoir J, Senet P, Lazareth I, et al.

426   Reproducibility of capillaroscopic classifications of systemic sclerosis: results from the

427   SCLEROCAP study. Rheumatology (Oxford). 2017;56(10):1713-20.

428   14.   Light RJ. Measures of Response Agreement for Qualitative Data - Some

429   Generalizations and Alternatives. Psychol Bull. 1971;76(5):365-&.

430   15.   Landis JR, Koch GG. The measurement of observer agreement for categorical data.

431   Biometrics. 1977;33(1):159-74.

432   16.   Cutolo M, Melsens K, Herrick AL, Foeldvari I, Deschepper E, De Keyser F, et al.

433   Reliability of simple capillaroscopic definitions in describing capillary morphology in

434   rheumatic diseases. Rheumatology (Oxford). 2018;57(4):757-9.

435   17.   Cutolo M, Smith V. Nailfold capillaroscopy and other methods to assess the

436   microvasculopathy in systemic sclerosis. 2013 September 2013-June 2014. In: Third EULAR

437   On-line Course on Systemic Sclerosis [Internet]. Third. [129-38].

438   18.   Smith V, Beeckman S, Herrick AL, Decuman S, Deschepper E, De Keyser F, et al. An

439   EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe

440   capillary morphology in rheumatic diseases. Rheumatology (Oxford). 2016;55(5):883-90.

441   19.   Ingegnoli F, Gualtierotti R, Lubatti C, Zahalkova L, Meani L, Boracchi P, et al.

442   Feasibility of different capillaroscopic measures for identifying nailfold microvascular

443   alterations. Seminars Arthritis Rheum. 2009;38(4):289-95.

444   20.   Hudson M, Masetto A, Steele R, Arthurs E, Baron M, Canadian Scleroderma Research

445   G. Reliability of widefield capillary microscopy to measure nailfold capillary density in

446   systemic sclerosis. Clin Exp Rheumatol. 2010;28(5 Suppl 62):S36-41.

447   21.   Hofstee HM, Serne EH, Roberts C, Hesselstrand R, Scheja A, Moore TL, et al. A

448   multicentre study on the reliability of qualitative and quantitative nail-fold videocapillaroscopy

449   assessment. Rheumatology (Oxford). 2012;51(4):749-55.

450   22.   Sekiyama JY, Camargo CZ, Eduardo L, Andrade C, Kayser C. Reliability of widefield

451   nailfold capillaroscopy and video capillaroscopy in the assessment of patients with Raynaud's

452   phenomenon. Arthritis Care Res. 2013;65(11):1853-61.

453   23.   Dinsdale G, Moore T, O'Leary N, Berks M, Roberts C, Manning J, et al. Quantitative

454   outcome measures for systemic sclerosis-related Microangiopathy - Reliability of image

455   acquisition in Nailfold Capillaroscopy. Microvasc Res. 2017;113:56-9.

456   24.   Dinsdale G, Moore T, O'Leary N, Tresadern P, Berks M, Roberts C, et al. Intra-and

457   inter-observer reliability of nailfold videocapillaroscopy - A possible outcome measure for

458   systemic sclerosis-related microangiopathy. Microvasc Res. 2017;112:1-6.

459   25.   Murray AK, Moore TL, Manning JB, Taylor C, Griffiths CE, Herrick AL. Noninvasive

460   imaging techniques in the assessment of scleroderma spectrum disorders. Arthritis Rheum.

461   2009;61(8):1103-11.

462   26.   Maricq HR, Harper FE, Khan MM, Tan EM, LeRoy EC. Microvascular abnormalities

463   as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue

464   disease. Clin Exp Rheumatol. 1983;1(3):195-205.

465

466

CONTRIBUTORS

491   Bouayed Kenza, Department of Pediatric Rheumatology, Children hospital CHU IBN Rochd,

492   Casablanca, Morocco; Boyadzhieva Vladimira, Department of Rheumatology, UMHAT St

493   Ivan Rilski, Sofia, Bulgaria; Brites Luisa, Department of Rheumatology, Centro Hospitalar e

494   Universitario de Coimbra, Coimbra, Portugal; Broen Jasper, Department of Rheumatology,

495   University Medical Center (UMC) Utrecht, Utrecht, The Netherlands; Carton Charlotte,

496   Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Cazac Victor,

497   Department of Rheumatology, State University of Medicine and Pharmacy of the Republic of

498   Moldova, Romania; Chetouane Radia, Department of Rheumatology, Hôpital De Ben Aknoun

499   Boukhroufa Abdelkader, Ben Aknoun, Algeria; Chodorowski Jakub, Department of

500   Dermatology, Own Practice, Lublin, Poland; Ciaffi Jacopo, Department of Rheumatology,

501   Leiden University Medical Center (LUMC), Leiden, The Netherlands; Cirillo Mariateresa,

502   Department of Rheumatology, Humanitas Clinical and Research Center, Milan, Italy; Coleiro

503   Bernard, Department of Rheumatology, Hospital Mater Dei, Belo Horizonte, Malta; Condeiro

504   Ines, Department of Rheumatology, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte

505   EPE, Lisboa, Portugal; Corrado Campochiaro, Department of Rheumatology, San Raffaele

506   Scientific institute Milan, Italy; Crisafulli Francesca, Department of Rheumatology, Spedali

507   Civili di Brescia, Brescia, Italy; Damyana Yordanova, Department of Rheumatology, St Ivan

508   Rilski   Hospital,   Sofia,   Bulgary;   Danczak-Pazdrowska   Aleksandra,   Department   of

509   Dermatology, Poznan University of Medical Sciences, Poznan, Poland; De Angelis Rossella,

510   Department of Clinical and Molecular Sciences, Rheumatology Unit, Carlo Urbani Hospital,

511   Polytechnic University of Marche, Jesi, Ancona, Italy; de Kanter Meeke, Department of

512   Rheumatology, Elisabeth-TweeSteden Ziekenhuis (ETZ), Tilburg, The Netherlands; De Moor

513   Michael, Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; de Vries-

514   Bouwstra Jeska, Department of Rheumatology, Leiden University Medical Center (LUMC),

515   Leiden, The Netherlands; Del Waldo Francesco, University of Leeds, Leeds, UK; Depicker

28

516   Anais, Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Devis

517   Benfaremo, Department of Rheumatology, Clinica Medica Universita Politecnica delle

518   Marche, Italy; Dhamo Blerina, Department of Rheumatology, Hygeia hospital Tirana, Tirana,

519   Albania; Dharmanand Balebail, Department of Rheumatology, Sakra Hosptial, Bangalore,

520   India; Dias Catarina, Department of Internal medicine, Central Hospital in Madeira Island,

521   Madeira, Portugal; Diogo Miranda Fonseca, Department of Rheumatology, Centro Hospitalar

522   Vila Nova de Gaia/Espinho, Vil Nova de Gaia, Portugal; Dudra-Jastrzebska Monika,

523   Department of Dermatology, Medical university of Lublin, Lublin, Poland; Eirijes Sami,

524   Department of Rheumatology, Rambam Medical Center, Haifa, Israel; Emperiale Valentina,

525   Department of Rheumatology, Hospital Universitario Principe de Asturias, Alcalá de Henares,

526   Spain; Eshak Nouran, Department of Rheumatology, Faculty of Medicine, University of

527   Alexandria, Alexandria, Egypt; Fage Simon W., Department of Dermatology, Aarhus

528   University Hospital, Arhus, Denmark; Farina Eleonora, Università degli Studi di Milano-

529   Bicocca, Milan, Italy; Ferdinand Isabelle, Clinique Notre-Dame De Grâce, Charleroi, Belgium;

530   Fernandez-Codina Andreu, Department of Rheumatology, Saint Josephs' Hospital London,

531   London Health Sciences Centre, London, UK; Frech Tracy, Department of Internal medicine,

532   University of Utah, Utah, USA; Gajdarji Olga, Department of Pediatrics, Institute of mother

533   and child, Warsaw, Poland; Galanopoulos Nikolaos, Department of Rheumatology, Democritus

534   University of Thrace, Alexandroupolis, Greece; Gallo Carolina, Department of Rheumatology,

535   Hospital Clinico San Borja Arriaran, Santiago, Chile; Gaulo dos suulg Sara, Department of

536   Rheumatology, Centro Hospitalar Sao Joao, Porto, Portugal; Gercik Onay, Department of

537   Rheumatology, Izmir Katip Çelebi University, Izmir, Turkey; Gheorghe Karina, Department of

538   Rheumatology, Karolinska University Hospital, Stockholm, Sweden; Giacomo De Luca,

539   Department of Rheumatology, IRCCS San Raffaele Hospital Milan, Milan, Italy; Glas Kasper,

540   Department of Rheumatology, Leiden University Medical Center (LUMC), Leiden, The

541 Netherlands; Gonçalves Maria Joao, Department of Rheumatology, Centro Hospitalar de
542 Lisboa Ocidental, EPE, Lisboa, Portugal; Gonzalez Benitez Roberto Daniel, Department of
543 Rheumatology, University Hospital Quironsalud Madrid, Madrid, Spain; Gruszecka Katarzyna,
544 Department of Rheumatology, Warsaw Medical University, Warsaw, Poland; Gruszecka
545 Katarzyna, Department of Rheumatology, Warsaw Medical University, Warsaw, Poland;
546 Guerboukha Hamida, Department of Rheumatology, Hôpital De Ben Aknoun Boukhroufa
547 Abdelkader, Ben Aknoun, Algeria; Gunnarsson Karin, Department of Rheumatology,
548 Karolinska University Hospital, Stockholm, Sweden; Havaro Fretheim, Department of
549 Rheumatology, University of Oslo, Oslo, NORWAY; Hindi Issam, Department of
550 Rheumatology, Hadassah Medical Center, Jerusalem, Israel; Hinze Tanja, Department of
551 Rheumatology, University Hospital Muenster, Muenster, Germany; Host Lauren, Department
552 of Rheumatology, Department of Rheumatology, University College London, Royal Free
553 Hospital, London, UK; Hoxha Ariela, Department of Internal medicine, University-Hospital of
554 Padova, Padova, Italy; Huang Po-Hao, Department of Internal medicine, China Medical
555 University Hospital, Taiwan, China; Ickinger Claudia, Department of Rheumatology,
556 University of the Witwatersrand, Johannesburg, South-Afrika; Isabelle Catherine, Department
557 of Rheumatology, Greenfield Park, Quebec, Canada; Ismail M Sherif, Department of
558 Rheumatology, National Research Center Egypt, Cairo, EGYPT; Jacqueline Lemmers,
559 Department of Rheumatology, Radboud University Medical Center (UMC), Nijmegen, The
560 Netherlands; Jakubaszek Michal, Department of Rheumatology, National Institute of
561 Geriatrics, Warsaw, Poland; Johannes Pflugfelder, Department of Rheumatology,
562 Marienhospital Stuttgart, Stuttgart, Germany; Kane Baidi Sy, Department of Internal medicine,
563 Cheikh Anta Diop University, Dakar, Senegal; Kata Viktoria, Department of Rheumatology,
564 University of Pécs, Pécs, Hungary; Kedor Claudia, Department of Rheumatology, Charité
565 Universtätsmedizin Mitte, Berlin, Germany; Kersten Brigit, Department of Rheumatology,

566 Radboud University Medical Center (UMC), Nijmegen, The Netherlands; Kerstens Floor,

567 Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands; Keskitalo

568 Paula, Department of Rheumatology, University of Oulu, Oulu, Finland; Khan Ali Khalid,

569 Department of Rheumatology, Al Zahra Hospital Dubai, Dubai, United Arab Emirates;

570 Khmelinskii Nikita, Department of Rheumatology, Hospital de Santa Maria, Centro Hospitalar

571 Lisboa Norte EPE, Lisboa, Portugal; Kienast Antonia, Department of Rheumatology, Zentrum

572 Kinderrheumatology Hamburg, Hamburg, Germany; Klein-Wieringa Inge, Department of

573 Rheumatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands;

574 Koulouri Angeliki, Department of Dermatology, Centre Hospitalier Universitaire Vaudois,

575 Lausanne, Switzerland; Kucharz Eugene, Department of Rheumatology, Medical University

576 of Silesia, Katowice, Poland; Kyllönen Minna, Department of Internal medicine, University of

577 Oulu, Oulu, Finland; Lazzaroni Maria-Grazia, Department of Rheumatology, Spedali Civili di

578 Brescia, Brescia, Italy; Lee Ying Hsuan, Department of Rheumatology, China Medical

579 University Hospital, Taiwan, China; Leone C Maria, Department of Scleroderma Unit,

580 University of Perugia, Perugia, Italy; Lescoat Alain, Department of Immunology, Centre

581 Hospitalier Universitaire de Rennes, France; Lopes Carina, Department of Rheumatology,

582 Hospital Egas Moniz, Lisbon, Portugal; Lopez-Ceron Ana, Department of Rheumatology,

583 Hospital Gregorio Marañón, Madrid, Spain; Lötscher Fabian, Department of Rheumatology,

584 Asklepios Klinik Altona, Hamburg, Germany; Luis Mariana, Department of Rheumatology,

585 Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal; Lukinac Ana Marija,

586 Department of Rheumatology, Clinical Hospital Center Osijek, Osijek, Croatia; Ly Khue,

587 Department of Internal medicine, McGill University, Montreal, Canada; Lynch Bernadette,

588 Department of Rheumatology, University hospital Galway, Galway, Ireland; Machado Ana

589 Rita, Department of Rheumatology, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte

590 EPE, Lisboa, Portugal; Madeira Nathalie, Department of Rheumatology, Instituto Portugues de

591 Reumatologia, Portugal; Mahieu Ine, Ghent University Hospital, Ghent, Belgium; Malgorzata-

592 Michalska Jakubus, Department of Dermatology, Medical university of Lublin, Lublin, Poland;

593 Martinez Robles Elena, Department of Internal medicine, Hopital Cantoblanco, Madrid, Spain;

594 Martins Patricia, Department of Rheumatology, Hospital de Santa Maria, Centro Hospitalar

595 Lisboa Norte EPE, Lisboa, Portugal; Mazzocchi Daniela, Department of Rheumatology,

596 Azienda Ospedaliera Ospedali di Legnano, Legnano, Italy; Medina Yimy, Department of

597 Internal medicine, National University of Colombia, Bogota, Colombia; Medjadi Mohsine,

598 Department of Rheumatology, E.H Ain El Turck Oran, Oran, Algeria; Melsens Karin,

599 Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Messiniti

600 Valentina, Department of Rheumatology, Universita della Campania L. Vanvitelli, Italy;

601 Miziolek Bartosz, Department of Dermatology, Medical University of Silesia, Katowice,

602 Poland; Moiseev Alexey, Department of Rheumatology, Lomonosov Moscow State University,

603 Moscow, Russia; Moser Florentin, Department of Rheumatology, St. Olavs hospital,

604 Trondheim University Hospital, Trondheim, Norway; Mrsic Fanika, Department of

605 Rheumatology, Clinical Hospital Sisters of Mercy, Zagreb, Croatia; Nemanja Damjanov,

606 Department of Rheumatology, University of Belgrade, Belgrade, Serbia; Neto Agna,

607 Department of Rheumatology, Centro Hospitalar de Lisboa Occidental, Hospital de Egas

608 Moniz, Lisboa, Portugal; Nguyen Thanh Hien Tu, Department of Internal medicine, Hôpital de

609 la cité de la santé, Laval, Canada; Osman Mohamed, Department of Rheumatology, University

610 of Alberta, Edmonton, Alberta, Canada; Ostrovrsnik Jaka, Department of Rheumatology,

611 University clinical center Ljubljana, Ljubljana, Slovenia; Pacini Greta, Department of

612 Rheumatology, University of Genoa, IRCCS San Martino Polyclinic Hospital, Genoa, Italy;

613 Patanè Massimo, Department of Rheumatology, University of Genoa, IRCCS San Martino

614 Polyclinic Hospital, Genoa, Italy; Pendolino Monica, Department of Rheumatology, Sapienza

615 University of Rome, Rome, Italy; Perdan-Pirkmajar Katja, Department of Rheumatology,

616 University clinical center Ljubljana, Ljubljana, Slovenia; Pettiti Giorgio, Department of

617 Rheumatology, S. Croce e Carle Hospital, Cuneo, Italy; Pham Michael, Department of Internal

618 medicine, Stanford Hospital, California, United states of America; Phaneuf Maude, Department

619 of Internal medicine, Hopital Honore Mercier, Quebec, Canada; Piette Yves, Department of

620 Rheumatology, Ghent University Hospital, Ghent, Belgium; Pomîrleanu Daniela Cristina,

621 Department of Rheumatology, Grigore T. Popa University of Medicine and Pharmacy, Iaşi,

622 Romania; Pontalti Marco, Department of Rheumatology, AOUI Verona, Verona, Italy; Poriau

623 Stefaan, Department of Rheumatology, AZ Zeno, Knokke, Belgium; Prate Ana Rita,

624 Department of Rheumatology, Centro Hospitalar Universitario de Croacia, Zagreb, Croatia;

625 Predoiu Andreea, Department of Rheumatology, Cluj County Hospital, Cluj-Napoca, Romania;

626 Pretel Ruiz Paula, Department of Rheumatology, Hospital Universitario Principe de Asturias,

627 Madrid, Spain; Priora Marta, Department of Rheumatology, l'Università di Pavia, Pavia, Italy;

628 Puneet Mashru, Department of Rheumatology, Jaslok Hospital and Research Centre, Mumbai,

629 INDIA; Radic Mislav, Department of Rheumatology, UH Split, Split, Croatia; Radovits Bea,

630 Department of Rheumatology, Bernhoven Hospital, Bernhoven, The Netherlands; Rakhma

631 Yanti Hellmi, Department of Rheumatology, Kariadi Hospital, Java, Indonesia; Raquel Miriam,

632 Department of Rheumatology, Hospital de S. João, Porto, Portugal; Rein Siv Elisabeth,

633 Department of Rheumatology, St. Olavs hospital, Trondheim University Hospital, Trondheim,

634 Norway; Reynaert Valerie, Department of Dermatology, Vrije Universiteit Brussel, Brussels

635 University Hospital, Brussels, Belgium; Rinzis Mirela Gabriela, Department of Rheumatology,

636 Sanovil clinic, Sanovil, Romania; Romanowska-Prochnicka Katarzyna, Department of

637 Rheumatology, National institute of geriatrics, Warsaw, Poland; Ross Laura, Department of

638 Rheumatology, Saint Vincent's hospital, Melbourne, Australia; Rovera Guido, Department of

639 Rheumatology, Ospedale Ordine Mauriziano di Torino, Umberto I, Italy; Ruiz Danilo Garas,

640 Department of Rheumatology, Federal university of Tocantins, Palmas, Brazil; Russo Barbara,

641 Department of Immunology, University of Geneva, Geneve, Switzerland; Rusu Ioana,

642 Department of Rheumatology, Cluj County Hospital, Cluj-Napoca, Romania; Saavedra

643 Gutierrez Silvana, Department of Rheumatology, Hospital clinico Universidad de Chile,

644 Santiago, Chile; Satis Hasar, Department of Rheumatology, Gazi University, Ankara, Turkey;

645 Schoneveld Leonard, Department of Rheumatology, Bravis hospital, Utrecht, The Netherlands;

646 Seitz Luca, Department of Rheumatology, Hospital Bern, Bern, Switzerland; Senoh Alkemi,

647 Department of Dermatology, Japanese red cross medical center, Tokyo, Japan; Sentosa

648 Anindita, Department of Rheumatology, Changi general hospital, simei, Singapore; Seyed

649 Mardani, Department of Rheumatology, Urmia University of Medical Sciences, Urmia, India;

650 Shah Qutab, Department of Rheumatology, Midlands Regional Hospital Tullamore Offaly,

651 Ireland; Sidi Narimene, Department of Rheumatology, Algiers hospital, Algiers, France;

652 Sikova Marinsz, Department of Dermatology, Warsaw Medical University, Warsaw, Poland;

653 Silva Filipa Daniela, Department of Internal medicine, , Portugal; Silvestri Valeria, Department

654 of Vascular surgery, Sapienza university of Rome, Rome, Italy; Simopolou Theodora,

655 Department of Rheumatology, University hospital of Larissa, Larissa, Greece; Singh Rajneet,

656 Department of Rheumatology, Galway Hospital, Galway, Ireland; Smith Vanessa, Department

657 of Rheumatology, Ghent University Hospital, Ghent, Belgium; Smits Marijn, Department of

658 Rheumatology, Radboud University Medical Center (UMC), Nijmegen, The Netherlands;

659 Snow Marcus, Department of Rheumatology, University of Nebraska, Lincoln, USA; Soldano

660 Stefano, Department of Internal medicine, University of Genoa, Genoa, Italy; Soto Lilian,

661 Department of Rheumatology, Universidad de Chile, Santiago, Chile; Soyfoo Shahnawaz

662 Muhammad, Department of Rheumatology, Hôpital Erasme ULB, Brussel, Belgium; Spierings

663 Julia, Department of Rheumatology, University Medical Center (UMC) Utrecht, Utrecht, The

664 Netherlands; Steelandt Alexia, Department of Rheumatology, Institut Cochin, Paris, France;

665 Stevens Wendy, Department of Rheumatology, Sint Vincent's Hospital, Melbourne, Australia;

666 Stoilov Nikolay, Department of Rheumatology, Medical university of Sofia, Sofia, Bulgaria;

667 Strugariu Georgiana, Department of Rheumatology, Clinical Rehabilitation Hospital, Lasi,

668 Romania; Suitner Manon, Department of Rheumatology, Université de Montreal, Montreal,

669 Canada; Sulli Alberto, Department of Rheumatology, University of Genoa, IRCCS San Martino

670 Polyclinic Hospital, Genoa, Italy; Supe Marijana, Department of Internal medicine, General

671 Hospital Sibenik, Sibenik, Croatia; Suput Skvarca Dasa, Department of Rheumatology,

672 Ljubljana University Medical Centre, Ljubljana, Slovenia; Suryo Anggoro Kusumo Wibowo,

673 Department of Internal medicine, Universitas Indonesia Cipto Mangunkusumo Hospital,

674 Jakarta, Indonesia; Tandrup Nielsen Christoffer, Copenhagen University Hospital,

675 Rigshospitalet, Copenhagen, Denmark; Tarasova Anna, Department of Rheumatology, Russian

676 Medical Academy of Postgraduate Education, Moscow, Rusia; Tardito Samuele, Department

677 of Rheumatology, University of Genoa, IRCCS San Martino Polyclinic Hospital, Genoa, Italy;

678 Tavor Yonit, Department of Rheumatology, Rambam Medical Center, Haifa, Israel; Tenazinha

679 Catarina, Department of Rheumatology, Hospital de Santa Maria, Centro Hospitalar Lisboa

680 Norte EPE, Lisboa, Portugal; Thoma Anna, Department of Rheumatology, Medical Center

681 Prodorso, Zurich, Switzerland; Tjeuw michael, Department of Rheumatology, Private Practice,

682 Sydney, Australia; Trombetta Amelia, Department of Internal Medicine, University of Genoa,

683 IRCCS San Martino Polyclinic Hospital, Genoa, Italy; Valido Ana, Department of

684 Rheumatology, Klinički Bolnički Centar (KBC) Split, Split, Croatia; van den Hoogen F.,

685 Department of Rheumatology, Radboud University Medical Center (UMC), Nijmegen, The

686 Netherlands; Van Herwaarden Noortje, Department of Rheumatology, Radboud University

687 Medical Center (UMC), Nijmegen, The Netherlands; Van Meerendonck Aniek, Department of

688 Rheumatology, VUMC Amsterdam, Amsterdam, The Netherlands; Van Spil Erwin,

689 Department of Rheumatology, University Medical Center (UMC) Utrecht, Utrecht, The

690 Netherlands; Vanden Bulcke Michael, Department of Rheumatology, Ghent University

691   Hospital, Ghent, Belgium; Vasco C Romao, Department of Rheumatology, Hospital de Santa

692   Maria, Centro Hospitalar Lisboa Norte EPE, Lisboa, Portugal; Verduci Elisa, Department of

693   Rheumatology, ASST Great Metropolitan Niguarda, Italy; Verniers Lucas, Department of

694   Internal medicine, Ghent University Hospital, Ghent, Belgium; Vivar Nancy, Department of

695   Rheumatology, Karolinska University Hospital, Stockholm, Sweden; Voigt Karen, Department

696   of Rheumatology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Vos Ine,

697   Department of Rheumatology, GZA Hospital Sint-Augustinus, Antwerp, Belgium; Wiefel

698   Kristin, Department of Rheumatology, University Hospital Dresden, Dresden, Germany;

699   Wojteczek Anna, Department of Internal medicine, Medical University of Gdańsk, Gdansk,

700   Poland; Yokochi Ritsuko, Department of Rheumatology, University of Tokyo, Chiba

701   University Medical Center, Tokyo, Japan; Zampogna Guiseppe, Department of Rheumatology,

702   Azienda Sanitaria dell' Alto Adige, Bolzano, Italy.

703 **TABLES AND FIGURES**

704 **Table 1: Mean Cohen's kappa (95% CI) and Light's kappa for the groups of raters at the**

705 **8th EULAR course on capillaroscopy in Rheumatic Diseases (Genoa 2018).**

706 **Table 2: Mean Cohen's kappa (95% CI) and Light's kappa for the groups of raters at the**

707 **8th EUSTAR course on SSc (Nijmegen 2019).**

708

709

710 **Figure 1: The "Fast Track algorithm".**

711 **Figure 2: Examination setting.**

712 **Figure 3: Inter-rater agreement assessed by kappa coefficients.**

713

714 **Table 1: Mean Cohen's kappa (95% CI) and Light's kappa for the groups of raters at the**

715 **8th EULAR course on capillaroscopy in Rheumatic Diseases (Genoa 2018).**

Group of raters	Mean Cohen's kappa (95% CI)	Light's kappa
Expert raters (n=6)	1	1
Attendees (n=135)	0.96 (0.95 – 0.98)	0.92
- *"Novices" (n=68)*	0.98 (0.96 – 0.99)	0.95
- *"Moderately experienced" (n=53)*	0.96 (0.93 – 0.99)	0.91
- *"Experienced" (n=14)*	0.93 (0.85 – 1)	0.84

716 *CI: Confidence Interval.*

717

38

718 **Table 2: Mean Cohen's kappa (95% CI) and Light's kappa for the groups of raters at the**

719 **8th EUSTAR course on SSc (Nijmegen 2019).**

| Group of raters	Mean Cohen's kappa (95% CI)	Light's kappa
Expert raters (n=3)	1	1
Attendees (n=85)	0.94 (0.92 – 0.96)	0.87
- *"Novices" (n=47)*	0.93 (0.90 – 0.96)	0.85
- *"Moderately experienced" (n=29)*	0.94 (0.89 – 0.98)	0.88
- *"Experienced" (n=9)*	0.97 (0.92 – 1)	0.94

720 *CI: Confidence Interval.*

721

722 **Figure 1: The "Fast Track algorithm".**

FAST TRACK ALGORITHM

Easy rule of thumb to discern an image as belonging to the scleroderma pattern or not
(Category 1: NON-scleroderma pattern; Category 2: Scleroderma pattern)

Rule 1 If density ≥7* AND If there are NO giants Then NO scleroderma pattern → Then your image belongs to **Category 1**

Rule 2 *If density is extremely lowered (± 3 or less), check for late scleroderma pattern OR if there are giants → Then your image belongs to **Category 2**

Rule 3 In all the other cases, the image belongs as per default to **Category 1**

723

724   The Fast Track algorithm" consists of three easy rules: 1) **Rule 1**: a capillary density ≥ 7

725   capillaries AND the absence of giant capillaries allows the rater to call the capillaroscopic

726   image a "non-scleroderma pattern (category 1)"; 2) **Rule 2**: an extremely lowered capillary

727   density (≤ 3 capillaries) in combination with abnormal shapes (i.e. "late scleroderma pattern")

728   OR the presence of giant capillaries allows the capillaroscopist to call the capillaroscopic image

729   "a scleroderma pattern (category 2)"; 3) **Rule 3**: if the image does not meet rule number 1 or

730   rule number 2 then the image is automatically classified as a "non-scleroderma pattern

731   (category 1)".

732 **Figure 2: Examination setting.**

733 After the teaching lecture, the PowerPoint slide of the "Fast Track algorithm" was projected in

734 the room during the whole examination (A) and the attendees had the picture of the "Fast Track

735 algorithm" at hand during the examination (B).

736 **Figure 3: Inter-rater agreement assessed by kappa coefficients.**

737 Inter-rater agreement was assessed by calculating kappa coefficients, i.e. the mean Cohen's

738 kappa (A) and Light's kappa (B). A) **Mean Cohen's kappa** was calculated to obtain the inter-

739 rater agreement for each rater (expert/ attendees/ "novices"/ "moderately experienced"/

740 "experienced") versus the principal expert (VS). B) **Light's kappa** was calculated to obtain the

741 inter-rater agreement for each possible combination of agreement between raters and the

742 principal expert (VS).

KEY MESSAGES

- The EULAR SG MC/RD created as first a clinical expert based fast track decision algorithm to categorize capillaroscopic images.

- Using the "Fast Track algorithm", non-trained capillaroscopists can discern a "non-scleroderma" from a "scleroderma pattern".

- Multicenter evaluation of the "Fast Track algorithm" shows excellent inter-rater reliability for categorizing capillaroscopic images.

750 **SUPPLEMENTARY FILES**

751 **Supplementary File 1: Standard capillaroscopic characteristics that are being evaluated**

752 **by the EULAR Study Group on Microcirculation in Rheumatic Diseases.**

753 **Supplementary File 2: Examination set.**

754 **Supplementary File 3: Application of the "Fast Track Algorithm" to exemplary images**.